What did Fisher & Paykel Healthcare Corporation Limited announce?
Fisher & Paykel Healthcare Corporation Limited (NZX: FPH) filed “2026 Annual Shareholders Meeting Speeches and Presentation” with NZX on 24 August 2026, as an agm announcement.
From the announcement:“Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) has provided the attached Chair’s speech and CEO’s slide presentation for the 2026 Annual Shareholders’ Meeting today.”
- When was it filed?
- 24 August 2026
- Where is the original?
- NZX announcement
2026 Annual Shareholders Meeting Speeches and Presentation
News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)
2026 Annual Shareholders’ Meeting Speech and Presentation
Auckland, New Zealand, 25 August 2026 – Fisher & Paykel Healthcare Corporation Limited (NZX:FPH,
ASX:FPH) has provided the attached Chair’s speech and CEO’s slide presentation for the 2026 Annual
Shareholders’ Meeting today.
There is no new material information contained within the speech or the presentation.
The speech and presentation are available on the company’s website at:
www.fphcare.com/nz/corporate/investor/events/.
Fisher & Paykel Healthcare’s Annual Shareholders’ Meeting is scheduled for 2pm NZST, 12pm AEST
(10pm USEDT) on Tuesday 25 August. To participate, go to: www.virtualmeeting.co.nz/fph26.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems
for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The
company’s products are sold in over 120 countries worldwide. For more information about the
company, visit our website www.fphcare.com.
Contacts
Media
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911
Investors
Daniel Adolph
Head of Investor Relations
daniel.adolph@fphcare.co.nz
+64 22 511 4050
Authorised by Raelene Leonard, General Counsel and Company Secretary.
---
1
FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
ANNUAL SHAREHOLDERS’ MEETING
25 AUGUST 2026
ADDRESS BY NEVILLE MITCHELL
BOARD CHAIR
Ladies and gentlemen, it is a privilege to address you again as Chair of your Board. In my address today, I
will share the Board's perspective on the company's progress and long-term priorities. Lewis will then
provide more detail on our financial and operational performance.
Fisher & Paykel Healthcare is guided by a unifying purpose – improving care and outcomes of patients.
One measure of success is the number of patients who benefit from our products and therapies. Last year,
this number was approximately 24 million people worldwide.
It was also another strong year financially. For the 2026 financial year, operating revenue increased to
$2.31 billion, net profit after tax increased to $468.5 million, and the Board approved total dividends of 52
cents per share. These outcomes reflect the strength of a business that has been built over many years
across products, therapies, geographies and markets.
In this industry, long-term value is created by continuing to improve products, expand clinical
understanding, and identify new ways to support patients and clinicians. Our shareholders will be familiar
with our strong commitment to research and development. In the 2026 financial year, the company invested
$235.5 million in R&D. This level of investment is critical to sustaining innovation, expanding our clinical
impact and ensuring a strong pipeline of future products.
Product innovation requires talented people, specialised equipment and spaces for collaboration,
development and testing. Here at our East Tāmaki campus, you can see that work has progressed on our
fifth building. The new facility will provide additional space for product development, manufacturing and
warehousing, and it is on track to open around the middle of 2027.
As a Board, we remain disciplined in our approach to major capital investments. You may recall that we
have purchased land to develop a second New Zealand campus in Karaka, and we continue to see this as
an attractive location. We also see opportunities for growth beyond New Zealand. As directors, spending
time in the regions where we operate is an important part of our oversight responsibility, and last year, the
Board visited our operations in China. We gained a deeper understanding of one of the world's fastest-
growing healthcare markets and engaged directly with key people there. Over the next year, we will be
looking to expand our manufacturing footprint in China to complement our ongoing investment in New
Zealand, Mexico and other regions.
2
As the company continues to grow, maintaining our culture globally becomes increasingly important. The
people of Fisher & Paykel Healthcare care deeply about patients, as well as their coworkers. They have a
relentless desire to improve, value original thinking, approach their work with humility, and work together for
the greater good. We believe the culture remains one of the company's greatest strengths and an important
contributor to long-term performance. Your Board recognises this and continues to monitor our progress.
I would now like to cover a few other matters that have received attention from the Board this year.
First, the topic of sustainable procurement and addressing modern slavery risks. This year, New Zealand
introduced a Modern Slavery Bill into Parliament that would create a regulatory framework requiring large
organisations to identify, address, and report on modern slavery risks within their operations and supply
chains. We believe companies have a responsibility to understand the conditions under which their
products are made and sourced, and we have robust processes in place to guide procurement decisions.
As part of our belief in “doing the right thing,” we work with our suppliers to raise awareness about modern
slavery risks and support them to address this issue. We already report under Australian, British and
Canadian legislation on this matter.
Second, an update on the composition of the Board. Last year we farewelled Pip Greenwood, and Anna
Curzon was appointed in February. Anna has brought a wealth of knowledge in the technology and
financial services industries to the Board. She is up for election today and will speak to you later in the
agenda. We continue to support the Future Directors programme, and we were fortunate to welcome
Margie Apa as our Future Director for this term. You may already be familiar with Margie, as she is the
former CEO of Health New Zealand.
Third, ahead of the vote today, I would like to say a few words on non-executive director remuneration. As
shareholders would expect, attracting and retaining high-calibre directors is important for effective
governance. The Board periodically reviews non-executive director remuneration with the assistance of
external advisers to ensure it remains appropriate for the responsibilities involved and competitive with
comparable organisations. This year, we have recommended changes in director remuneration, and these
are outlined in Explanatory Note 3 of the Notice of Meeting.
In closing, I would like to return to a theme I discussed last year: long-term thinking.
We are operating in a world that is increasingly complex. F&P operates in over 120 different countries, so
world events are important. Supply chains remain exposed to disruption. Healthcare systems are under
pressure. Geopolitics, trade policies and tariffs have continued to be important considerations. We do not
underestimate these challenges; they require careful oversight and steady decision-making. We have
3
continued to follow these issues closely and have met with experts in New Zealand and overseas to
navigate them. In this regard, we acknowledge MFAT and the advice they provide us.
We cannot control external events, but we can maintain our long-term view. This guides our decisions. The
company’s success does not rest on a single year’s performance. It rests on a consistent strategy,
innovative products, a strong culture, and trust earned over many years. Those are the foundations the
Board is focused on protecting and strengthening.
On behalf of the Board, thank you to our people, customers, suppliers and shareholders for your continued
support.
ADDRESS BY LEWIS GRADON
MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER
Please refer to separate slide presentation.
---
1
Annual Shareholders' Meeting
25 August 2026
2
Mark Cross
Your Board
Neville MitchellLewis Gradon
Sir Michael Daniell
Anna Curzon
Cather Simpson
Graham McLean
Lisa McIntyre
3
Agenda
•Chair’s Address
•Managing Director and Chief Executive Officer’s Address
•Financial Statements
•Resolutions
•Voting
•General Questions
4
Neville Mitchell
Board Chair
NZ Campus 1 - Building 5
28,000 m
2
/ 300,000 ft
2
NZ Campus 2 - Karaka
Future second campus in South Auckland
7
8
Mark Cross
Your Board
Neville MitchellLewis Gradon
Sir Michael Daniell
Anna Curzon
Cather Simpson
Graham McLean
Lisa McIntyre
9
Anna Curzon
New director
10
Margie Apa
Future Director
11
Neville Mitchell
Board Chair
12
Lewis Gradon
Managing Director
and CEO
13
FY26 financial highlights
Operating Revenue
$2.31B12% (cc)
Net Profit After Tax
$468.5M28% (cc)
Constant currency growth rates
Gross Margin
63.7%
122
bps
Hospital Hardware
27% (cc)
14
10-year trends
Constant currency growth rates
$0.0b
$0.5b
$1.0b
$1.5b
$2.0b
$2.5b
1617181920212223242526
Revenue
FY26
$2.31B
12%
$0m
$100m
$200m
$300m
$400m
$500m
$600m
1617181920212223242526
Net Profit After Tax
FY26
$468.5M
28%
15
Dividends
0c
10c
20c
30c
40c
50c
60c
20162017201820192020202120222023202420252026
CPS (NZ cents)
Interim CPSFinal CPSTotal CPS
FY26 Final Dividend
33cps
38%
FY26 Total Dividend
52cps
22%
Dividend history FY16 - FY26
10-year DPS CAGR
12%
Global trade and
world events
17
FY27 first half outlook
At 31 July exchange rates*, guidance assumptions for the first half of the 2027 financial
year include a continuation of the current trading environment and result in:
•Operating revenue of approximately $1.24 billion
•Net profit after tax of approximately $280 million.
This would equate to approximately 14% growth in reported operating revenue and
approximately 24% growth in net profit after tax (excluding the impact of US tariff
refunds), compared to the first half of the 2026 financial year.
*31 July 2026 exchange rates of NZD:USD 0.59, NZD:EUR 0.51, NZD:MXN 10.17.
18
FY27 full year outlook
At 31 July exchange rates*, our full year guidance is for:
•Operating revenue in the range of approximately $2.47 billion to $2.57 billion
•Net profit after tax in the range of approximately $525 million to $565 million.
The first half and full year net profit after tax guidance incorporates $23 million in US
IEEPA tariff refunds.
The full year outlook assumes current global tariff rates, policies and applications for
the duration of this financial year and continues to anticipate an overall improvement in
gross margin.
*31 July 2026 exchange rates of NZD:USD 0.59, NZD:EUR 0.51, NZD:MXN 10.17.
19
Building momentum for the future
FY2021FY2026ChangeComment
People in Research & Development68496942%
R&D spend averaging 10.6% of
revenue over five years.
Patents in the United States381768102%
Our global patent portfolio now
numbers more than 4,500.
People in Sales, Marketing &
Distribution
1,2301,56827%
A direct sales presence in 55 countries
vs. 45 in FY21.
Nasal high flow (NHF) clinical practice
guidelines
512+7
~3,200 studies cumulatively published
over five years.
Number of professional societies or
groups with anesthesia guidelines
recommending/acknowledging NHF
~10~25+~15
Guidelines span several strategic
markets including North America, UK,
France, and Australia/NZ.
Hospital hardware revenueApproximately ~$880m in cumulative hospital hardware revenue from FY2022 to FY2026.
20
Gross margin recovery
45%
50%
55%
60%
65%
FY22FY23FY24*FY25FY26
Our 5-year margin history
Long-term gross margin target
*Underlying gross margin excludes the product recall provision
21
Revenue growth since 2001
$0
$500
$1,000
$1,500
$2,000
$2,500
200120062011201620212026
Revenue (NZ$m)
Revenue in NZ$ millions by financial year
~24 million patients
$2.31 billion revenue
22
Neville Mitchell
Board Chair
23
Financial statements
•Opportunity for shareholders to ask any questions specifically on the financial
statements, the auditor’s report or the company’s 2026 annual report.
•There will be an opportunity to ask any general questions once all items on the
agenda have been considered.
24
Resolutions
1.Election of Anna Curzon
2.Auditor’s Remuneration
3.Directors’ Remuneration
4.Discretionary Long Term Variable Remuneration to Lewis Gradon
5.Issue of Performance Share Rights – North America
6.Issue of Share Options – North America
7.Issue of Employee Share Rights – North America
25
How to vote online
Voting box
Question box
Help line
26
Neville Mitchell
Board Chair
27
Resolution 1: Election of Anna Curzon
That Anna Curzon, who being eligible,
offers herself for election, be elected as a
Director of the company.
Click “Submit Vote” to lodge your vote.
Need help?
Call the MUFG Corporate Markets helpline
0800 200 220
28
Resolution 2: Auditor’s Remuneration
That the Directors be authorised to fix the
fees and expenses of PwC as the
company’s auditor.
Click “Submit Vote” to lodge your vote.
Need help?
Call the MUFG Corporate Markets helpline
0800 200 220
29
Resolution 3: Directors’ Remuneration
That the maximum aggregate annual
remuneration payable to non-executive
Directors be increased by NZ$350,000
from NZ$1,750,000 to NZ$2,100,000
(plus GST as appropriate).
Click “Submit Vote” to lodge your vote.
Need help?
Call the MUFG Corporate Markets helpline
0800 200 220
30
Resolution 4: Discretionary Long Term Variable Remuneration
That the grant of discretionary long term
variable remuneration instruments to
Lewis Gradon, Managing Director and
Chief Executive Officer, be approved.
Click “Submit Vote” to lodge your vote.
Need help?
Call the MUFG Corporate Markets helpline
0800 200 220
31
Resolution 5: Issue of Performance Share Rights
That the Fisher & Paykel Healthcare
Corporation Limited 2025 Performance
Share Rights Plan – North America be
approved.
Click “Submit Vote” to lodge your vote.
Need help?
Call the MUFG Corporate Markets helpline
0800 200 220
32
Resolution 6: Issue of Share Options
That the Fisher & Paykel Healthcare
Corporation Limited 2025 Share Option
Plan – North America be approved.
Click “Submit Vote” to lodge your vote.
Need help?
Call the MUFG Corporate Markets helpline
0800 200 220
33
Resolution 7: Issue of Employee Share Rights
That the Fisher & Paykel Healthcare
Corporation Limited Employee Share
Rights Plan – North America be approved.
Click “Submit Vote” to lodge your vote.
Need help?
Call the MUFG Corporate Markets helpline
0800 200 220
34
Neville Mitchell
Board Chair
35
Questions
Questions
36
Thank you for attending today’s
Annual Shareholders' Meeting
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.